This is the new website for acrobiosystems.com. We would love to hear what you think of it - please send feedback

Welcome to ACROBiosystems

0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B-Cell Maturation Antigen (BCMA), a Target for Multiple Myeloma

B-Cell Maturation Antigen (BCMA), a Target for Multiple Myeloma

BCMA is selectively induced during plasma cell differentiation and is nearly absent on naive and memory B cells (Avery et al., 2003; Chiu et al., 2007). The interaction between BCMA and its ligand BAFF and APRIL is involved for the maintenance of long-lived plasma cells (O'Connor et al., 2004; Peperzak et al., 2013). BCMA is an ideal target for cancers of plasma cells, because it’s not expressed in other major organs. Dozens of BCMA-targeting therapies, including chimeric antigen receptor T (CAR-T) cells, antibody-drug conjugate, and Bi-specific antibodies, are currently being developed and tested clinically. Leading the pack is Bluebird and Celgene’s bb2121. A phase I multi-center clinical trial has demonstrated a stunning 80% response rate in multiple myeloma patients. These approaches, if successfully established, will bring multiple myeloma patients a much needed option beyond Daratumumab (anti-CD38 antibody) and Elotuzumab (anti-SLAMF7).

BCMA-LP.jpg

The interactions between BAFF / APRIL and their receptors are selective. Note BCMA can interact with both BAFF and APRIL (Bolkun et al., 2016). The affinity of APRIL-BCMA interaction, however, is much higher than that of BAFF-BCMA binding (Bossen and Schneider, 2006).

ACROBiosystems provides a comprehensive panel of BCMA proteins, including the exclusive biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). We also offer BCMA related proteins, such as BAFF and BAFFR proteins.

Product Highlight

BAF-H4268-E2.jpg
Fig. 1 Immobilized Human BAFF, Fc Tag (Cat. No. BAF-H4268) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, Fc Tag (Cat. No. BC7-H82F0) with a linear range of 0.12-1.95 ng/mL.
BCMA-purity.png
Fig. 2 The purity of Human BCMA, His Tag (Cat. No. BCA-H522y) is greater than 93% as determined by SEC-HPLC.

We offer a variety of ready-to-use biotinylated proteins using our in-house developed labeling techniques, which confer high bioactivity and minimal batch-to-batch variation. In addition, we also offer FITC-labeled BCMA and BAFF proteins.

BCMA Product List

MoleculeCat. No.SpeciesStructurePurityFeatures
BCMA
(Biotin-labeled)
BC7-H82F0BC7-H82F0-STC1
BCMA
(FITC-Labeled)
BCA-HF254BCA-HF254-STC1
BCMABCA-H522yBCA-H522y-STC1
BCMABC7-H5254BC7-H5254-STC1
BCMA
(Biotin-labeled)
BCA-M82F0BCA-M82F0-STC1
BCMA
(Biotin-labeled)
BCA-M5258BCA-M5258-STC1
BCMA
(Biotin-labeled)
BCA-C82F4BCA-C82F4-STC1
BCMABCA-C5253BCA-C5253-STC1

Other Relevant Products

MoleculeCat. No.SpeciesStructurePurityFeatures
BAFF
(Biotin-labeled)
BAF-H82F3BAF-H82F3-STC1
BAFF
(Biotin-labeled)
BAF-H82Q2BAF-H82Q2-STC1
BAFF
(FITC-Labeled)
BAF-HF268BAF-HF268-STC1
BAFFBAF-H4218BAF-H4218-STC1
BAFFBAF-H4268BAF-H4268-STC1
BAFFBAF-H5248BAF-H5248-STC1
BAFFR
(Biotin-labeled)
BAR-M82F0BAR-M82F0-STC1
BAFFRBAR-M5259BAR-M5259-STC1
BAFFRBAR-H5257BAR-H5257-STC1

Other Multiple Myeloma Targets

MoleculeCat. No.SpeciesStructurePurityFeatures
CD38
(Biotin-labeled)
CD8-H82E7CD8-H82E7-STC1
CD38CD8-H5224CD8-H5224-STC1
SLAMF7
(Biotin-labeled)
SL7-H82E0SL7-H82E0-STC1
SLAMF7SL7-H5225SL7-H5225-STC1
SLAMF7SL7-H5256SL7-H5256-STC1

References

Related Articles

This web search service is supported by Google Inc.